| Literature DB >> 17869514 |
Peter Ballard1, Bernard C Barlaam, Robert H Bradbury, Allan Dishington, Laurent F A Hennequin, D Mark Hickinson, Ian M Hollingsworth, Jason G Kettle, Teresa Klinowska, Donald J Ogilvie, Stuart E Pearson, James S Scott, Abid Suleman, Robin Whittaker, Emma J Williams, Robin Wood, Lindsay Wright.
Abstract
Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compounds. A representative compound 8a inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacology primarily reflecting inhibition of erbB2 receptor tyrosine kinase.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17869514 DOI： 10.1016/j.bmcl.2007.08.073
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823